Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2151811 | 0.78 | CYP2D6 (0.31) | CYP2D6CA2CA1CA7DGAT1 | |
| SCHEMBL10512876 | 0.78 | DGAT1 (0.36) | CYP2D6CA2CA1CA7DGAT1 | |
| SCHEMBL1580190 | 0.77 | NOS1 (0.33) | CYP2D6CA2CA1CA7 | |
| SCHEMBL14945698 | 0.76 | DGAT1 (0.34) | CYP2D6CA2CA1CA7DGAT1 | |
| SCHEMBL12033651 | 0.74 | DGAT1 (0.33) | CYP2D6CA2DGAT1HDAC3HDAC1 | |
| SCHEMBL17643549 | 0.74 | CYP2D6 (0.37) | CYP2D6CA2DGAT1HDAC3HDAC1 | |
| SCHEMBL5676122 | 0.74 | — | — | |
| SCHEMBL5896909 | 0.74 | CYP2D6 (0.32) | CYP2D6CA2CA1CA7DGAT1 | |
| SCHEMBL5896905 | 0.74 | CYP2D6 (0.32) | CYP2D6CA2CA1CA7DGAT1 | |
| SCHEMBL12865444 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709678-B2 | Method for producing asymmetric alkyl compound using alkali-treated solid support, and alkali-treated solid support used in this method | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-05-04 | — | — | US | disclosed |
| US-20070225157-A1 | Method for Producing Asymmetric Alkyl Compound Using Alkali-Treated Solid SAupport, and Alkali-Treated Solid Support Used in this Method | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1693362-A1 | PROCESS FOR PRODUCTION OF ASYMMETRIC ALKYL COMPOUNDS WITH ALKALI-TREATED SOLID CARRIER AND ALKALI-TREATED SOLID CARRIER TO BE USED IN THE PROCESS | Japan Science and Technology Agency (JP) | 2006-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225157-A1 | Method for Producing Asymmetric Alkyl Compound Using Alkali-Treated Solid SAupport, and Alkali-Treated Solid Support Used in this Method | AGPAT5, SKP1, NPEPPS | CYP2D6 3393/4885CA2 477/4885CA1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.